{
    "nct_id": "NCT02260674",
    "title": "A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Safety and Tolerability of JNJ-54861911 in Subjects With Early Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2025-04-25",
    "description_brief": "The purpose of this study is to evaluate the long-term safety and tolerability of JNJ-54861911 during 6 months of treatment in participants with early (predementia) alzheimer's disease (AD \\[degenerative disease of the brain characterized by the insidious onset of dementia, impairment of memory, judgment, attention span, and problem solving skills are followed by severe apraxias and a global loss of cognitive abilities\\]).",
    "description_detailed": "This is a double-blind (neither the researchers nor the participants know what treatment the participant is receiving), placebo-controlled (an inactive substance; a pretend treatment \\[with no drug in it\\] that is compared in a clinical trial with a drug to test if the drug has a real effect), randomized (study drug assigned by chance), multi-center (when more than one hospital or medical school team work on a medical research study), parallel-group study. The study consists of 3 Parts; Screening Phase of 90 days, double-blind Treatment Phase of 6 months and Follow-up Phase of 7 to 28 days following the last dose in Month 6. Eligible participants in the early (predementia) AD spectrum will be randomized to either Treatment group 1, 2 or placebo and participants who previously participated in study 54861911ALZ1005 will be enrolled in this study and will receive the same treatment as in study 54861911ALZ1005. The study duration for each participant will be approximately 10 months. Blood and cerebrospinal fluid (CSF) samples will be collected to evaluate the plasma pharmacokinetics of JNJ-54861911, as well as amyloid beta fragments. Participants' safety will be monitored throughout the study, including magnetic resonance imaging (MRI) and cognitive measures.",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "JNJ-54861911 (atabecestat) \u2014 oral BACE1 inhibitor"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The study tests JNJ-54861911 in early (predementia) AD to evaluate safety/tolerability. The drug is described in the literature as atabecestat (JNJ-54861911), an oral inhibitor of BACE1 (\u03b2-secretase) intended to reduce production of amyloid-\u03b2 \u2014 i.e., a mechanism that targets AD pathology rather than only symptomatic cognition. \ue200cite\ue202turn0search0\ue202turn0search1\ue201",
        "Act: Web search confirms JNJ-54861911 = atabecestat, a small-molecule, brain-penetrant BACE1 inhibitor developed by Janssen; phase 1\u20132 studies showed robust CSF A\u03b2 reductions and the compound advanced into larger EARLY trials. Clinical reports also note development was halted after liver enzyme elevations and dose-related cognitive worsening in later trials. These sources support classification as a disease-targeted small molecule (amyloid-targeting). \ue200cite\ue202turn0search1\ue202turn0search6\ue202turn0search2\ue201",
        "Reflect: Classification check \u2014 atabecestat is not a biologic (no monoclonal antibody or vaccine), it is a small-molecule enzyme inhibitor that modulates amyloid production (disease-modifying mechanism), so the correct category is 'disease-targeted small molecule'. There is no indication the trial tests a cognitive-only symptomatic enhancer or a neuropsychiatric intervention. Trial registration and PD publications back this interpretation. \ue200cite\ue202turn0search0\ue202turn0search1\ue201"
    ],
    "agent_type": "A) Amyloid beta",
    "explanation_agent": [
        "Reason: The investigational drug JNJ-54861911 (atabecestat) is a brain\u2011penetrant, oral small\u2011molecule inhibitor of BACE1 (\u03b2\u2011secretase) designed to reduce production of amyloid\u2011\u03b2 peptides, i.e., it directly targets amyloid pathology rather than providing only symptomatic benefit. \ue200cite\ue202turn0search4\ue202turn0search3\ue201",
        "Act: The trial description and literature identify JNJ\u201154861911 = atabecestat and its mechanism as BACE1 inhibition with robust CSF A\u03b2 reductions in early AD studies; therefore the most specific CADRO match is A) Amyloid beta. (Relevant trial reports and pharmacodynamic studies confirm identity/mechanism.) \ue200cite\ue202turn0search4\ue202turn0search1\ue201",
        "Reflect: Classification check \u2014 atabecestat is a disease\u2011targeted small molecule that modulates amyloid production (not a tau, inflammatory, synaptic, or purely symptomatic agent), so A) Amyloid beta is the correct CADRO category. Safety findings (elevated liver enzymes and cognitive signals that led to program termination) are consistent with trial reports but do not change the mechanism-based category. \ue200cite\ue202turn0search2\ue202turn0search0\ue201",
        "Web search results used (key sources): 'Pharmacodynamics of atabecestat (JNJ\u201154861911), an oral BACE1 inhibitor in patients with early Alzheimer\u2019s disease' (full text, PMC). \ue200cite\ue202turn0search4\ue201  'Long\u2011term safety and tolerability of atabecestat (JNJ\u201154861911) ...' (Alzheimer's Research & Therapy / PubMed). \ue200cite\ue202turn0search2\ue202turn0search0\ue201  Additional PubMed summary of pharmacodynamics and CSF A\u03b2 reductions. \ue200cite\ue202turn0search3\ue201"
    ]
}